JP2004536103A5 - - Google Patents

Info

Publication number

JP2004536103A5

JP2004536103A5 JP2003509100A JP2003509100A JP2004536103A5 JP 2004536103 A5 JP2004536103 A5 JP 2004536103A5 JP 2003509100 A JP2003509100 A JP 2003509100A JP 2003509100 A JP2003509100 A JP 2003509100A JP 2004536103 A5 JP2004536103 A5 JP 2004536103A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

resistant

oligodeoxynucleotide

composition according

synthetic

Prior art date

2002-05-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 14
• 230000000692 anti-sense effect Effects 0.000 claims description 11
• 208000018360 neuromuscular disease Diseases 0.000 claims description 6
• 230000000750 progressive effect Effects 0.000 claims description 6
• 101000801359 Homo sapiens Acetylcholinesterase Proteins 0.000 claims description 5
• 108020004999 messenger RNA Proteins 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 4
• 108010022752 Acetylcholinesterase Proteins 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims description 2
• 230000008685 targeting Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 12
• 101710163270 Nuclease Proteins 0.000 claims 10
• 239000002773 nucleotide Substances 0.000 claims 10
• 125000003729 nucleotide group Chemical group 0.000 claims 9
• 108091034117 Oligonucleotide Proteins 0.000 claims 4
• 239000000074 antisense oligonucleotide Substances 0.000 claims 4
• 238000012230 antisense oligonucleotides Methods 0.000 claims 4
• 206010049565 Muscle fatigue Diseases 0.000 claims 2
• 239000013543 active substance Substances 0.000 claims 2
• 210000003169 central nervous system Anatomy 0.000 claims 2
• 229940079593 drug Drugs 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 210000003205 muscle Anatomy 0.000 claims 2
• 206010028417 myasthenia gravis Diseases 0.000 claims 2
• 210000000715 neuromuscular junction Anatomy 0.000 claims 2
• 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
• 230000001105 regulatory effect Effects 0.000 claims 2
• 230000007103 stamina Effects 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 229940124596 AChE inhibitor Drugs 0.000 claims 1
• 102100033639 Acetylcholinesterase Human genes 0.000 claims 1
• 206010003591 Ataxia Diseases 0.000 claims 1
• 208000029578 Muscle disease Diseases 0.000 claims 1
• 208000021642 Muscular disease Diseases 0.000 claims 1
• 206010033799 Paralysis Diseases 0.000 claims 1
• 208000034189 Sclerosis Diseases 0.000 claims 1
• 230000005856 abnormality Effects 0.000 claims 1
• 239000004480 active ingredient Substances 0.000 claims 1
• 125000003158 alcohol group Chemical group 0.000 claims 1
• 125000001931 aliphatic group Chemical group 0.000 claims 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
• 239000003242 anti bacterial agent Substances 0.000 claims 1
• 229940088710 antibiotic agent Drugs 0.000 claims 1
• 125000002843 carboxylic acid group Chemical group 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• -1 chemotherapeutics Substances 0.000 claims 1
• 230000001684 chronic effect Effects 0.000 claims 1
• 150000001875 compounds Chemical class 0.000 claims 1
• 239000002872 contrast media Substances 0.000 claims 1
• 230000007547 defect Effects 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 125000004185 ester group Chemical group 0.000 claims 1
• 238000001415 gene therapy Methods 0.000 claims 1
• 125000003010 ionic group Chemical group 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 201000006938 muscular dystrophy Diseases 0.000 claims 1
• 230000002980 postoperative effect Effects 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 230000007832 reinnervation Effects 0.000 claims 1
• 230000000153 supplemental effect Effects 0.000 claims 1
• 230000016978 synaptic transmission, cholinergic Effects 0.000 claims 1
• 239000013076 target substance Substances 0.000 claims 1
• 239000013598 vector Substances 0.000 claims 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1